Drug and vaccine safety

Drug and vaccine safety

WHO / A. Zaidi / WHO / M. Nieuwenhof / WHO / A. Jallanzo
A health worker gives free medicine to patients in district headquarters hospital (DHQ) Kasur. At the Cholera treatment center in Beira. Guinea: Ebola outbreak response
© Credits

Overview

Patient safety is fundamental to delivering quality essential health services.

Research to improve detection, assessment, and prevention of the adverse effects of medicines and vaccines, as well as research to strengthen pharmacovigilance systems for safe and effective introduction of new health technologies such as new TB treatments will ultimately contribute to enhancing patient care and patient safety.  

   

TDR’s contribution to improving patient safety

ShORRT initiative

ShORRT initiative

Overview

 

In the latest World Health Organization (WHO) guidelines on drug-resistant tuberculosis (DR-TB) treatment, modifications to the recommended all-oral treatments for multidrug- and rifampicin-resistant (MDR/RR) TB and novel regimens for patients with extensively drug-resistant TB are encouraged under operational research conditions. 

 

Other activities

Implementation research on Adverse Drug Reaction reporting

Supporting countries to conduct implementation research to understand bottlenecks and challenges to reporting of adverse events and help determine effective and sustainable methods for drug safety monitoring (Uganda, The Philippines, Malawi, Burkina Faso).

Partnerships

The Access and Delivery Partnership